All In Biotech

Drug Trial Radar · NCT01241344

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

A Randomized, Placebo-controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment With CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation

Last checked: Nov 19, 2026Latest source record: Jul 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Nov 2010

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Nov 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 months, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to assess the safety and efficacy of preemptive treatment with oral brincidofovir (BCV), as compared to placebo, for the prevention of adenovirus (AdV) disease in recipients of hematopoietic stem cell transplantation (HCT) with asymptomatic AdV viremia.

Conditions

  • Adenovirus Disease

Interventions

  • BrincidofovirDrug

    * Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets). * Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).

  • PlaceboOther

    Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets). • Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinically Significant AdV InfectionTime frame: 12 weeks

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • Pheonix Children's Hospital

    Phoenix, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • Childrens hospital of LA

    Los Angeles, California

  • CHOC Children's Hospital

    Orange, California

  • University of California, San Francisco

    San Francisco, California

  • Lucile Packard Childrens hopsital at Stanford

    Stanford, California

  • The Children's Hospital-Denver

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Indiana University

    Indianapolis, Indiana

  • LSU Health Sciences Center New Orleans Childrens Hospital

    New Orleans, Louisiana

  • Harvard-Children's Hospital Boston

    Boston, Massachusetts

  • Univeristy of Minnesota

    Minneapolis, Minnesota

  • St. Louis Children's Hosptial

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan Kettering

    New York, New York

  • New York Medical College

    Valhalla, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • St. Judes Children's Research Hospital

    Memphis, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • UT Southwestern

    Dallas, Texas

  • Baylor College of Medicine, Texas Childrens Hospital

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Methodist Hospital

    San Antonio, Texas

  • Primary Children's Medical of Utah

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.